Here is the rundown on market activity for Boston Scientific Corporation C (NYSE:BSX). David A. Pierce, Sr VP sold $379,736 worth of shares at an average price of $28.00 on Fri the 9th. The Sr VP now owns $677,628 of the stock as reported to the SEC. EVP Timothy A. Pratt sold 10,000 shares at an average price of $27.13 on Thu the 1st. That brings the EVP’s holdings to $5,855,902 as recorded in a recent Form 4 SEC filing.
Kevin J. Ballinger, EVP & Pres, Interven Cardio reported the sale of 28,864 shares of BSX stock. The shares were purchased at an average price of $26.13. The EVP & Pres, Interven Cardio now owns $1,498,974 of the stock per the Form 4 SEC filing.
Boston Scientific Corporation, launched on June 22, 1979, is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: interventional cardiology, cardiac rhythm management, endoscopy, peripheral interventions, urology and pelvic health, neuromodulation, and electrophysiology. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. It sells ACURATE TA and ACURATE neo /TF valve systems in Europe and in other geographies outside of the United States..
These firms have also modified their investment in BSX. Columbia Partners L L C Investment Management reduced its ownership by shedding 1,642 shares a decrease of 1.0% as of 03/31/2017. Columbia Partners L L C Investment Management now controls 170,044 shares with a value of $4,228,000. The value of the position overall is up by 13.9%. As of quarter end Ifm Investors Pty Ltd had acquired a total of 10,410 shares growing its position 60.9%. The value in dollars went from $370,000 to $684,000 increasing 84.9% for the reporting period.
As of the end of the quarter Aua Capital Management, LLC had bought 9,900 shares growing its stake by 270.5%. The value of the total investment in Boston Scientific Corporation C increased from $91,000 to $293,000 a change of $202,000 quarter over quarter. Piedmont Investment Advisors LLC grew its stake by buying 2,466 shares an increase of 0.9%. Piedmont Investment Advisors LLC currently owns 285,979 shares worth $7,112,000. The total value of its holdings increased 16.0%.
On October 6 Citigroup left the company rating at “Buy” but raised the price expectation to $29.00 from $23.00. On September 1 the company was upgraded from “” to “Buy” and a price target of $33.00 was set by Argus Research.
July 29 investment analysts at JP Morgan maintained a stock rating of “Hold” and moved up the price target from $18.00 to $24.00. On June 9 analysts at Guggenheim Securities released its first research report on the stock with a rating of “Buy”.
On May 23 the company was changed to a “Neutral” by BTIG Research a cut from the previous “” rating. Nomura added the stock to its research portfolio giving it an initial rating of “Buy” and a price target of $22.00.
The company is trading down since yesterday’s close of $27.82. Shares last traded at $27.75 which is just over the 50 day moving average of $26.67 and which is marginally over the 200 day moving average of $24.32. The 50 day moving average went up $1.08 or +4.04% whereas the 200 day moving average was up $3.43 or +14.13%.
The P/E ratio is 88.94 and market capitalization is 38.00B. In the latest earnings report the EPS was $0.31 and is estimated to be $1.25 for the current year with 1,369,401,000 shares outstanding. Next quarter’s EPS is expected be $0.31 and the next full year EPS is projected to be $1.42.